211 related articles for article (PubMed ID: 29017591)
1. Residual disease activity and treatment adjustments in psoriatic arthritis in current clinical practice.
van Mens LJJ; van de Sande MGH; Fluri IA; Atiqi S; van Kuijk AWR; Baeten DLP
Arthritis Res Ther; 2017 Oct; 19(1):226. PubMed ID: 29017591
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Composite Indices Tailored for Psoriatic Arthritis Treated with csDMARD and bDMARD: A Cross-sectional Analysis of a Longitudinal Cohort.
Lubrano E; De Socio A; Perrotta FM
J Rheumatol; 2017 Aug; 44(8):1159-1164. PubMed ID: 28572467
[TBL] [Abstract][Full Text] [Related]
3. Ten years of follow-up data in psoriatic arthritis: results based on standardized monitoring of patients in an ordinary outpatient clinic in southern Norway.
Haugeberg G; Michelsen B; Tengesdal S; Hansen IJW; Diamantopoulos A; Kavanaugh A
Arthritis Res Ther; 2018 Aug; 20(1):160. PubMed ID: 30071892
[TBL] [Abstract][Full Text] [Related]
4. Minimal disease activity and impact of disease in psoriatic arthritis: a Spanish cross-sectional multicenter study.
Queiro R; Cañete JD; Montilla C; Abad M; Montoro M; Gómez S; Cábez A;
Arthritis Res Ther; 2017 Mar; 19(1):72. PubMed ID: 28356155
[TBL] [Abstract][Full Text] [Related]
5. Impact of Clinical Specialty Setting and Geographic Regions on Disease Management in Patients with Psoriatic Arthritis in the United States: A Multicenter Observational Study.
Mease PJ; Liu C; Siegel E; Richmond H; Wu M; Chen L; Douglas K; Lockshin B
Am J Clin Dermatol; 2019 Dec; 20(6):873-880. PubMed ID: 31612380
[TBL] [Abstract][Full Text] [Related]
6. What Should Be the Primary Target of "Treat to Target" in Psoriatic Arthritis?
Coates LC; Lubrano E; Perrotta FM; Emery P; Conaghan PG; Helliwell PS
J Rheumatol; 2019 Jan; 46(1):38-42. PubMed ID: 30219765
[TBL] [Abstract][Full Text] [Related]
7. Residual disease activity in psoriatic arthritis: discordance between the rheumatologist's opinion and minimal disease activity measurement.
van Mens LJJ; Turina MC; van de Sande MGH; Nurmohamed MT; van Kuijk AWR; Baeten DLP
Rheumatology (Oxford); 2018 Feb; 57(2):283-290. PubMed ID: 28541484
[TBL] [Abstract][Full Text] [Related]
8. LOOP, a cross-sectional, observational study investigating the clinical specialty setting as a determinant of disease management in psoriatic arthritis: Subgroup analysis results from Japan.
Okada M; Kurimoto S; Ganz F; Boehncke WH
PLoS One; 2021; 16(1):e0245954. PubMed ID: 33503031
[TBL] [Abstract][Full Text] [Related]
9. Very Low Disease Activity, DAPSA Remission, and Impact of Disease in a Spanish Population with Psoriatic Arthritis.
Queiro R; Cañete JD; Montilla C; Abad MA; Montoro M; Gómez S; Cábez A;
J Rheumatol; 2019 Jul; 46(7):710-715. PubMed ID: 30709957
[TBL] [Abstract][Full Text] [Related]
10. Psoriatic arthritis in Canadian clinical practice: the PsA assessment in rheumatology.
Gladman DD; Chandran V; Thavaneswaran A; Zummer M
J Rheumatol; 2012 Sep; 39(9):1850-3. PubMed ID: 22859361
[TBL] [Abstract][Full Text] [Related]
11. Need for Improvement in Current Treatment of Psoriatic Arthritis: Study of an Outpatient Clinic Population.
Michelsen B; Diamantopoulos AP; Høiberg HK; Soldal DM; Kavanaugh A; Haugeberg G
J Rheumatol; 2017 Apr; 44(4):431-436. PubMed ID: 28148701
[TBL] [Abstract][Full Text] [Related]
12. Persistence of tumor necrosis factor inhibitor or conventional synthetic disease-modifying antirheumatic drug monotherapy or combination therapy in psoriatic arthritis in a real-world setting.
Mease PJ; Accortt NA; Rebello S; Etzel CJ; Harrison RW; Aras GA; Gharaibeh MMF; Greenberg JD; Collier DH
Rheumatol Int; 2019 Sep; 39(9):1547-1558. PubMed ID: 31321485
[TBL] [Abstract][Full Text] [Related]
13. Impact of skin, musculoskeletal and psychosocial aspects on quality of life in psoriatic arthritis patients: A cross-sectional study of outpatient clinic patients in the biologic treatment era.
Haugeberg G; Michelsen B; Kavanaugh A
RMD Open; 2020 May; 6(1):. PubMed ID: 32409518
[TBL] [Abstract][Full Text] [Related]
14. Residual symptoms and disease burden among patients with psoriatic arthritis: is a new disease activity index required?
Kilic G; Kilic E; Nas K; Kamanlı A; Tekeoglu İ
Rheumatol Int; 2019 Jan; 39(1):73-81. PubMed ID: 30426235
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous Response in Several Domains in Patients with Psoriatic Disease Treated with Etanercept as Monotherapy or in Combination with Conventional Synthetic Disease-modifying Antirheumatic Drugs.
Behrens F; Meier L; Prinz JC; Jobst J; Lippe R; Löschmann PA; Lorenz HM
J Rheumatol; 2018 Jun; 45(6):802-810. PubMed ID: 29606665
[TBL] [Abstract][Full Text] [Related]
16. Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs.
Strand V; de Vlam K; Covarrubias-Cobos JA; Mease PJ; Gladman DD; Graham D; Wang C; Cappelleri JC; Hendrikx T; Hsu MA
RMD Open; 2019; 5(1):e000806. PubMed ID: 30713721
[TBL] [Abstract][Full Text] [Related]
17. The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study.
Heiberg MS; Kaufmann C; Rødevand E; Mikkelsen K; Koldingsnes W; Mowinckel P; Kvien TK
Ann Rheum Dis; 2007 Aug; 66(8):1038-42. PubMed ID: 17213251
[TBL] [Abstract][Full Text] [Related]
18. Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA).
Theander E; Husmark T; Alenius GM; Larsson PT; Teleman A; Geijer M; Lindqvist UR
Ann Rheum Dis; 2014 Feb; 73(2):407-13. PubMed ID: 23355078
[TBL] [Abstract][Full Text] [Related]
19. Synovial features of patients with rheumatoid arthritis and psoriatic arthritis in clinical and ultrasound remission differ under anti-TNF therapy: a clue to interpret different chances of relapse after clinical remission?
Alivernini S; Tolusso B; Petricca L; Bui L; Di Sante G; Peluso G; Benvenuto R; Fedele AL; Federico F; Ferraccioli G; Gremese E
Ann Rheum Dis; 2017 Jul; 76(7):1228-1236. PubMed ID: 28119289
[TBL] [Abstract][Full Text] [Related]
20. Treating Psoriatic Arthritis to Target: Defining the Psoriatic Arthritis Disease Activity Score That Reflects a State of Minimal Disease Activity.
Perruccio AV; Got M; Li S; Ye Y; Gladman DD; Chandran V
J Rheumatol; 2020 Mar; 47(3):362-368. PubMed ID: 31203221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
